New Drug ' Transforming ' Outlook in Spinal Muscular Atrophy New Drug ' Transforming ' Outlook in Spinal Muscular Atrophy

Latest results from a phase 3 study of nusinersen show large improvements in motor function and survival, with some infants never predicted to sit up being able to walk. But can Biogen justify the high cost of the drug?Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news